Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0204
NEWS & VIEWS
|
The up and down of KRAS testing for personalized colorectal cancer treatment |
|
Affiliation: William CS Cho, Scientific Officer,
Department of Clinical Oncology, Queen Elizabeth Hospital, Room 1305, 13/F, Block R, 30 Gascoigne Road, Kowloon, Hong Kong.
Tel: +852 2958 5441; +852 2958 5455
E-mail: williamcscho@gmail.com;
chocs@ha.org.hk |
Since there is no abstract available we provide the first paragraph.
Recently, KRAS mutations testing has become popular in decision-making about the addition of EGFR inhibitors to chemotherapy in the treatment of patients with metastatic colorectal cancer (mCRC). A recent meta-analysis published in Clinical Colorectal cancer supports the clinical utility of KRAS genotyping for selecting patients with mCRC who are likely to respond to this treatment. However, the first phase 3 trial that has enrolled patients with KRAS mutation testing does not recommend this genetic testing. This letter describes the limitations of this meta-analysis and evaluates whether EGFR inhibitors should be administrated in mCRC patients based on KRAS mutational status.
(Citation: Gastric & Breast Cancer 2012; 11(1): 29-31)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 30 December 2011 |
|
